DDInter734 DDInter817
Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by _Clostridioides_ (formerly _Clostridium_) _difficile_ in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent. Fidaxomicin was the first macrocyclic lactone antibiotic with activity against _C. difficile_, and it displays a narrow spectrum of activity against gram-positive anaerobes. It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.
Fidaxomicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Amprenavir
Amprenavir {u} may lead to a major life threatening interaction when taken with {v} Gilteritinib
Fidaxomicin {u} (Compound) is included by {v} (Pharmacologic Class) Macrolides
Macrolides {u} (Pharmacologic Class) includes {v} (Compound) Clarithromycin
Clarithromycin {u} may lead to a major life threatening interaction when taken with {v} Gilteritinib
Fidaxomicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Atorvastatin
Atorvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Fidaxomicin {u} (Compound) causes {v} (Side Effect) Flatulence
Flatulence {u} (Side Effect) is caused by {v} (Compound) Amoxapine
Amoxapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Fidaxomicin {u} (Compound) is included by {v} (Pharmacologic Class) Macrolides
Macrolides {u} (Pharmacologic Class) includes {v} (Compound) Azithromycin
Azithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Fidaxomicin {u} (Compound) causes {v} (Side Effect) Flatulence
Flatulence {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gilteritinib
Fidaxomicin {u} (Compound) causes {v} (Side Effect) Decreased appetite
Decreased appetite {u} (Side Effect) is caused by {v} (Compound) Delavirdine
Delavirdine {u} may lead to a major life threatening interaction when taken with {v} Gilteritinib
Fidaxomicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Amprenavir (Compound) and Amprenavir may lead to a major life threatening interaction when taken with Gilteritinib
Fidaxomicin (Compound) is included by Macrolides (Pharmacologic Class) and Macrolides (Pharmacologic Class) includes Clarithromycin (Compound) and Clarithromycin may lead to a major life threatening interaction when taken with Gilteritinib
Fidaxomicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Atorvastatin (Compound) and Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Fidaxomicin (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Amoxapine (Compound) and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Fidaxomicin (Compound) is included by Macrolides (Pharmacologic Class) and Macrolides (Pharmacologic Class) includes Azithromycin (Compound) and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Fidaxomicin (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Fidaxomicin (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Delavirdine (Compound) and Delavirdine may lead to a major life threatening interaction when taken with Gilteritinib